Los Angeles Capital Management
RPRX icon

Los Angeles Capital Management’s Royalty Pharma RPRX Stock Holding History

Los Angeles Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2M Sell
877,674
-94,253
-10% -$4.91M 0.18% 117
2026
Q1 		$46.6M Sell
971,927
-257,109
-21% -$11.3M 0.18% 111
2025
Q4 		$45.4M Buy
1,229,036
+212,294
+21% +$8.1M 0.15% 105
2025
Q3 		$35.9M Buy
1,016,742
+699,991
+221% +$25.3M 0.12% 126
2025
Q2 		$11.4M Sell
316,751
-764,377
-71% -$25.3M 0.04% 230
2025
Q1 		$33.7M Buy
1,081,128
+1,040,234
+2,544% +$33M 0.15% 121
2024
Q4 		$1.04M Sell
40,894
-346,803
-89% -$9.2M ﹤0.01% 606
2024
Q3 		$11M Sell
387,697
-57,851
-13% -$1.6M 0.04% 241
2024
Q2 		$11.7M Sell
445,548
-258,371
-37% -$7.16M 0.04% 243
2024
Q1 		$21.4M Buy
703,919
+297,948
+73% +$8.78M 0.07% 206
2023
Q4 		$11.4M Sell
405,971
-25,575
-6% -$703K 0.04% 255
2023
Q3 		$11.7M Buy
431,546
+126,180
+41% +$3.75M 0.05% 229
2023
Q2 		$9.39M Sell
305,366
-241,368
-44% -$8.18M 0.04% 268
2023
Q1 		$19.7M Buy
546,734
+280,435
+105% +$10.4M 0.09% 196
2022
Q4 		$10.5M Buy
266,299
+98,126
+58% +$4.1M 0.05% 272
2022
Q3 		$6.76M Sell
168,173
-85,093
-34% -$3.63M 0.04% 317
2022
Q2 		$10.6M Sell
253,266
-41,133
-14% -$1.69M 0.05% 269
2022
Q1 		$11.5M Buy
294,399
+112,068
+61% +$4.4M 0.05% 262
2021
Q4 		$7.27M Sell
182,331
-158,648
-47% -$6.16M 0.03% 306
2021
Q3 		$12.3M Sell
340,979
-629,027
-65% -$24.4M 0.06% 246
2021
Q2 		$39.8M Buy
970,006
+80,255
+9% +$3.41M 0.18% 127
2021
Q1 		$38.8M Buy
889,751
+628,606
+241% +$29.8M 0.18% 131
2020
Q4 		$13.1M Buy
+261,145
New +$11.1M 0.06% 238

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's RPRX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Royalty Pharma (RPRX) stake by 9.7% in Q2 2026, selling an estimated $4.91M and leaving 877,674 shares worth $49.2M. The position accounts for 0.18% of the portfolio, ranked #117.

Los Angeles Capital Management first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Los Angeles Capital Management held 877,674 shares of Royalty Pharma worth $49.2M as of Q2 2026.
  • Los Angeles Capital Management sold 94,253 Royalty Pharma shares in Q2 2026, an estimated $4.91M.
  • Royalty Pharma made up 0.18% of Los Angeles Capital Management's portfolio in Q2 2026, its #117 holding.
  • Los Angeles Capital Management first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.